Cencora posts earnings miss but lifts EPS guidance

Short interest offers almost no story here — and that's itself informative. SI runs at around 2.5% of the free float, barely changed on the week (+0.4%) and lower over the past month after a brief spike in mid-April unwound quickly. Cost to borrow is just 0.49%, a level that signals no real urgency in the lending market. Availability remains very loose, meaning new shorts face no friction whatsoever. The options market is similarly measured: the put/call ratio of 0.63 is only marginally above its 20-day average of 0.62, suggesting options traders are not crowding into downside protection around this print. The ORTEX short score of 34.4 is mid-range and has barely moved over the past two weeks. Positioning, in short, looks entirely normal for a large-cap healthcare distributor.

The Street picture is more interesting. The consensus is technically a hold, with William Blair initiating coverage at Market Perform last week — one of the more recent signals of caution. Evercore ISI cut its price target to $360 from $420 in early April, the most aggressive trim in recent months, though it retained an Outperform. Bulls at JPMorgan, Wells Fargo, and Barclays have progressively lifted targets earlier in the year — JPMorgan at $419, Wells Fargo at $429, Barclays at $425 — but those levels were set against a price above $350. With the stock now closer to $306, the implied upside to those targets is around 32%, a gap that looks wide but reflects how far the stock has fallen. One data point worth noting: forward EPS growth sits in the 80th percentile of the universe on a year-over-year basis, suggesting the earnings trajectory remains well above average even if this quarter's top line disappointed. The dividend score also ranks in the 91st percentile; the company declared a $0.60 dividend today, keeping the income angle intact for longer-term holders.

Institutional positioning has a few notable threads. T. Rowe Price added 3.4 million shares in the quarter ending March — the largest incremental change among the top holders — bringing its stake to just over 7% of shares. FMR (Fidelity) added 1.6 million shares in the same period. Insider activity points the other direction: CEO Mauch sold stock three times between January and February at prices in the $354-$359 range, well above today's level. CFO James Cleary followed with a sale in March at $350. These were partially offset by restricted stock awards, but the net 90-day position in dollar terms is net selling of over $23 million. There is no obvious distress signal here — executives routinely sell for diversification — but the timing, above current levels, does not add a contrarian support signal.

The next thing to watch is how quickly the post-earnings analyst community digests the revised guidance framework. The Street's prior consensus models were built on revenue assumptions that no longer apply, and the reconvergence of price targets around a structurally lower top-line number — while reconciling a higher EPS path — is the recalibration exercise now underway.